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Summary  Ventricular  arrhythmias  are  frequent  in  patients  with  systemic  sclerosis  and  may
result  in  sudden  cardiac  death.  We  report  the  case  of  a  patient  with  systemic  sclerosis  and  recent
syncopes  in  whom  induction  of  unstable  sustained  ventricular  tachycardia  of  2  different  mor-
phologies  accompanied  by  syncopal  event  was  demonstrated  at  the  electrophysiological  study.deﬁbrillator;
Systemic  sclerosis
He  was  then  implanted  a  3rd  generation  implantable  cardioverter  deﬁbrillator  and  remained
thereafter  asymptomatic.  We  suggest  that  aggressive  testing  is  warranted  in  systemic  scle-
rosis  patients  with  suspected  malignant  arrhythmias  to  identify  candidates  for  deﬁbrillator
implantation  and  prevent  sudden  deaths.
f  Car
o
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ntroductionystemic  sclerosis  (SSc)  or  scleroderma  is  a  connective  tis-
ue disease  characterized  by  progressive  ﬁbrosis  of  the  skin
nd numerous  visceral  organs,  including  heart.  Depending
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n  the  extent  of  skin  involvement  and  pattern  of  other  clini-
al manifestations,  scleroderma  is  usually  classiﬁed  into  two
ain types:  diffuse  or  limited.  In  the  natural  clinical  course
f SSc,  various  cardiovascular  complications  may  occur,  most
requently  dysrhythmias  and  pulmonary  hypertension  [1—4].
t has  also  been  demonstrated  that  cardiac  autonomic  dys-
unction may  occur  in  SSc  [5—8].  However,  in  the  majority
f these  patients,  cardiovascular  manifestations  may  remain
ubclinical [1—4].
Rhythm and  conduction  disturbances  and  sudden  car-
iac death  (SCD)  are  frequent  in  autoimmune  rheumatic
isorders [9].  In  these  patients,  in  addition  to  standard
 Published by Elsevier Ltd. All rights reserved.
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12-lead  electrocardiogram  (ECG),  24-h  Holter  monitoring  is
most widely  applied  for  evaluation  of  patients  with  arrhyth-
mias and  conduction  abnormalities,  whereas  ECG  can  detect
a substrate  for  malignant  arrhythmias  and  identify  patients
who warrant  further  investigation.  Invasive  electrophysio-
logical studies  are  indicated  when  spontaneous  arrhythmias
are infrequent  and  when  life-threatening  sustained  arrhyth-
mia is  suspected.
Case report
We  report  the  case  of  a  male  patient  aged  33  years  affected
by SSc  at  the  ﬁrst  stadium,  documented  by  the  presence  of
typical clinical  features  (Raynaud’s  phenomenon,  telangiec-
tasia, dysphagia),  positivity  of  antinuclear  antibodies,  and
reporting syncope  twice  in  the  previous  6  months.
ECG  at  rest  showed  sinus  rhythm  with  QS  waves  from  V1
to V3  (Fig.  1);  echocardiographic  examination  demonstrated
mild ventricular  dilation  (left  ventricular  end  diastolic  diam-
eter 59  mm;  left  ventricular  end  systolic  diameter  47  mm)
with akinesia  of  the  apex  and  slight  reduction  of  systolic
function (ejection  fraction  =  45%)  in  the  absence  of  classic
cardiovascular risk  factors.
During  hospitalization,  the  patient  was  asymptomatic
for angina  and  dyspnea  but  symptomatic  for  palpitations.
His therapy  was  amiodarone  200  mg/day  and  bisoprolol
3.75 mg/day.  24-h  Holter  ECG  was  performed  reporting
over 20,000  polymorphic  premature  ventricular  contrac-
tions (PVCs)  arranged  in  pairs,  triplets,  and  non-sustained
ventricular tachycardia  (VT).  The  patient  then  underwent
coronary angiography  that  showed  the  absence  of  epicardial
t
r
adiogram  at  rest.
oronary  arteries  lesions.  Thereafter,  an  electrophysiolog-
cal test  was  performed  by  a  double  cannulation  of  the
emoral vein  with  2  diagnostic  quadripolar  leads  Damato
nd Cournard  curves  in  apex  of  the  right  ventricle  and  then
n right  ventricular  outﬂow  tract,  in  the  Hissian  region,
nd in  the  high  right  atrium.  The  patient  underwent  local
nesthesia with  2%  mepivacaine;  no  anti-arrhythmic  drugs
ere dispensed.  Normal  conduction  interval  at  rest  (RR
nterval 820  ms,  AH  100  ms,  HV  42  ms),  sinus  node  recov-
ry time  (<500  ms)  and  atrioventricular  nodal  refractory
eriod (320  ms)  were  registered.  During  programmed  stim-
lation of  the  right  ventricle  (at  a  cycle  length  of  500  ms)
y double  extrastimuli  (S2  200  ms,  S3  240  ms),  inducibility
f monomorphic  VT  was  observed  (Fig.  2)  (200  ms  cycle,
I and  AVL  negative,  upper  shaft,  precordial  transition  in
4). Consequently,  programmed  stimulation  of  the  right
entricle (at  a  cycle  length  of  400  ms)  by  triple  extrastim-
li (S2  200  ms,  S3  200  ms,  S4  200  ms)  was  performed  and
nducibility of  sustained  VT  of  2  different  morphologies
as demonstrated.  Additionally,  VT  was  accompanied  by  a
yncopal episode,  a  more  rapid  (170  ms)  cycle  and  ventric-
lar ﬁbrillation  (VF)  with  recovery  of  the  sinus  rhythm  by
C shock  (Fig.  3).  Morphologies  of  induced  VTs  resembled
he wave  of  non-sustained  VT  observed  on  Holter  monitor-
ng. During  the  electrophysiological  study,  easy  inducibility
f sustained  atrial  ﬁbrillation  with  restoration  of  sinus
hythm by  administration  of  150  mg  ﬂecainide  was  also
emonstrated.
Based on  clinical  data  and  results  of  electrophysiological
est, the  patient  was  implanted  a  DDDR  dual  chamber  deﬁb-
illator. After  6  months  of  follow-up,  the  patient  remained
symptomatic without  interventions  of  the  device.
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iscussion
his  case  demonstrates  that  the  electrophysiological  prop-
rties of  the  heart  are  noticeably  inﬂuenced  in  patients
ith progressive  SSc.  Conduction  tract  abnormalities  are
ommonly observed  in  patients  with  SSc.  Atrio-ventricular
onduction disorders  including  prolonged  PR  intervals  and
s
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Figure  3  Ventricular  ﬁbrillation  with  recovery  of  the with  degeneration  in  a  more  rapid  and  subsequent  ventricular
omplete  heart  block,  and  atrial  and  ventricular  tach-
arrhythmias are  frequently  noted  [10—14].
Transient  atrial  ﬁbrillation,  ﬂutter,  or  paroxysmal
upraventricular  tachycardia  may  be  present  in  20—30%
f SSc  patients.  Atrial  and  ventricular  arrhythmias  in
symptomatic patients  with  SSc  are  associated  with  poor
rognosis. Patchy  myocardial  ﬁbrosis  provides  the  substrate
 sinus  rhythm  by  cardioverter  deﬁbrillator  shock.
mic
[
[
[
[
[
[
[
[
[
[
[Implantable  cardioverter  deﬁbrillator  in  a  patient  with  syste
for  re-entrant  tachyarrhythmias.  Ventricular  arrhythmias
have been  reported  in  67%  [13]  and  non-sustained  VT  in
7—13% of  unselected  patients  with  SSc  [15].  Patients  with
frequent PVCs  had  50%  mortality  during  33  months  of  follow-
up in  contrast  to  8%  among  patients  without  frequent
ventricular ectopy.  Bulkley  et  al.  [16]  reported  SCD  in  21%
of patients  with  SSc  as  opposed  to  no  SCD  in  22%  of  subjects
observed by  Lee  et  al.  [17].
Our  patient  developed  ventricular  tachyarrhythmias  at
the electrophysiological  study,  with  the  induction  of  a  sus-
tained  VT  of  2  morphologies  that  degenerated  in  VF.  In
accordance with  the  literature  [18],  our  case  showed  the
presence of  QS  waves  from  V1  to  V3  at  ECG  and  high
frequency of  ventricular  arrhythmias  during  the  Holter  moni-
toring. However,  we  reported  uncommon  echocardiographic
data characterized  by  the  presence  of  mild  ventricular  dila-
tion with  reduction  of  ejection  fraction.
The  electrophysiological  ﬁndings  indicate  that  in  SSc,
abnormalities exist  in  cardiac  centers  of  impulse  forma-
tion and  conduction,  suggesting  that  electrical  instability
of heart  is  an  integral  clinical  feature  of  scleroderma
heart disease.  Since  these  ﬁndings  are  important  indices
of abnormal  electrophysiology,  it  is  evident  that  such
disorders are  due  to  SSc  pathologic  involvement  of  the
heart leading  to  ﬁbrosis  [19].  The  pathogenesis  of  ﬁbrosis
remains uncertain,  although  several  studies  have  suggested
that the  tissue  damage  may  be  related  to  either  anatomic
or functional  impairment  of  circulation  at  the  level  of
the intramyocardial  vasculature  [20—24].  These  alterations
could explain  the  akinesia  of  the  apex  found  at  echocardio-
graphy. Fibrosis  areas  could  be  the  foci  of  induced  VT  at  the
electrophysiological study.
Anti-arrhythmic  drug  therapy  is  the  mainstay  of  man-
agement. Drug  selection  is  based  upon  electrophysiological
effects and  type  of  arrhythmia.  VF  (except  in  the  ﬁrst  few
hours of  acute  myocardial  infarction)  and  medically  untreat-
able life-threatening  VT  are  indications  for  implantable
cardioverter deﬁbrillator  [25].  This  type  of  treatment  should
be  seriously  considered  in  patients  with  SSc  and  inducibility
of VF  unresponsive  to  drug  therapy  [26].
Conclusions
This  case  emphasizes  the  need  for  comprehensive  nonin-
vasive and  invasive  testing  for  malignant  arrhythmias  in
patients with  SSc  and  syncope  of  suspected  cardiac  ori-
gin. In  these  patients  myocardial  abnormalities  due  to  the
underlying disease  may  trigger  malignant  arrhythmias  in  the
absence of  severe  left  ventricular  dysfunction,  leading  to
the need  for  implantable  cardioverter  deﬁbrillator  implan-
tation before  fulﬁllment  of  current  guidelines  criteria.
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